Hormonal Contraceptives Market, by Product (Oral Contraceptive Pills, Injectable Birth Control, Emergency Contraceptive Pills, Vaginal Ring, and Transdermal Patches), by Hormone (Progestin Only Contraceptive and Combined Hormonal Contraceptive), by Age Gr

Hormonal Contraceptives Market, by Product (Oral Contraceptive Pills, Injectable Birth Control, Emergency Contraceptive Pills, Vaginal Ring, and Transdermal Patches), by Hormone (Progestin Only Contraceptive and Combined Hormonal Contraceptive), by Age Group (15–24 Years, 25–34 Years, 35–44 Years, and Above 44 Years), by End User (Hospitals, Homecare, Gynecology Centers, Clinics, and Ambulatory Surgical Centers), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Hormonal contraception is one of the contraceptive methods that act on the endocrine system. Several types of female hormones are used to prevent ovulation and avoid fertilization. Hormonal contraception can also cause changes in the uterus, making pregnancy less likely. Based on product, the market is segmented into oral contraceptive pills, injectable birth control, emergency contraceptive pills, vaginal ring and transdermal patches. These are safe and reliable forms of hormonal contraceptives to prevent pregnancy. Hormonal contraception has several potential benefits such as they can reduce the risk of uterine cancer, ovarian cancer, and colon cancer. They generally reduce menstrual (menstrual) blood flow. They can reduce painful periods and are very effective in preventing pregnancy.
Market Dynamics
Increased awareness about the benefits and use of contraceptives is a major factor driving the global hormonal contraceptives market. The ever-increasing global population, particularly in developing economies such as India, Brazil, China and others, is a growing source of concern around the world, necessitating government initiatives such as public awareness campaigns to eliminate or reduce the risk of unwanted pregnancies, abortion risks, and the threat of sexual disorders. For instance, according to data from the World Health Organization (WHO), 16 million girls between the ages of 15 and 19 give birth each year, which represents approximately 11% of all births in the world. To prevent these unintended births, the World Health Organization have launched global awareness programs such as "This is your life, this is your future". The London Family Planning Summit urged governments, international agencies and other private sectors to commit to improving the accessibility of voluntary family planning.
Key features of the study:
This report provides in-depth analysis of the global hormonal contraceptives market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global hormonal contraceptives market based on the following parameters – company highlights, types portfolio, key highlights, financial performance, and market strategies
Key companies covered as a part of this study include The Female Health Company, Teva Pharmaceutical Industries Limited, Bayer AG, Pfizer, Inc., Mylan N.V., Johnson & Johnson, Ansell Ltd., Mayer Laboratories, Merck & Co., Inc., Church & Dwight, Co., Inc., Afaxys, Inc., Allergan plc., Agile Therapeutics, Apothecus Pharmaceutical Corporation., Novartis AG, Sun Pharmaceutical Industries Ltd., and Cipla Limited.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global hormonal contraceptives market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hormonal contraceptives market
Detailed Segmentation:
Global Hormonal Contraceptives Market, By Product:
Oral Contraceptive Pills
Injectable Birth Control
Emergency Contraceptive Pills
Vaginal Ring
Transdermal Patches
Global Hormonal Contraceptives Market, By Hormone:
Progestin Only Contraceptive
Combined Hormonal Contraceptive
Global Hormonal Contraceptives Market, By Age Group:
15–24 Years
25–34 Years
35–44 Years
Above 44 Years
Global Hormonal Contraceptives Market, By End User:
Hospitals
Homecare
Gynecology Centers
Clinics
Ambulatory Surgical Centers
Global Hormonal Contraceptives Market, By Region:
North America
By Product
Oral Contraceptive Pills
Injectable Birth Control
Emergency Contraceptive Pills
Vaginal Ring
Transdermal Patches
By Hormone
Progestin Only Contraceptive
Combined Hormonal Contraceptive
By Age Group
15–24 Years
25–34 Years
35–44 Years
Above 44 Years
By End User
Hospitals
Homecare
Gynecology Centers
Clinics
Ambulatory Surgical Centers
By Country
U.S.
Canada
Latin America
By Product
Oral Contraceptive Pills
Injectable Birth Control
Emergency Contraceptive Pills
Vaginal Ring
Transdermal Patches
By Hormone
Progestin Only Contraceptive
Combined Hormonal Contraceptive
By Age Group
15–24 Years
25–34 Years
35–44 Years
Above 44 Years
By End User
Hospitals
Homecare
Gynecology Centers
Clinics
Ambulatory Surgical Centers
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Product
Oral Contraceptive Pills
Injectable Birth Control
Emergency Contraceptive Pills
Vaginal Ring
Transdermal Patches
By Hormone
Progestin Only Contraceptive
Combined Hormonal Contraceptive
By Age Group
15–24 Years
25–34 Years
35–44 Years
Above 44 Years
By End User
Hospitals
Homecare
Gynecology Centers
Clinics
Ambulatory Surgical Centers
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Product
Oral Contraceptive Pills
Injectable Birth Control
Emergency Contraceptive Pills
Vaginal Ring
Transdermal Patches
By Hormone
Progestin Only Contraceptive
Combined Hormonal Contraceptive
By Age Group
15–24 Years
25–34 Years
35–44 Years
Above 44 Years
By End User
Hospitals
Homecare
Gynecology Centers
Clinics
Ambulatory Surgical Centers
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Product
Oral Contraceptive Pills
Injectable Birth Control
Emergency Contraceptive Pills
Vaginal Ring
Transdermal Patches
By Hormone
Progestin Only Contraceptive
Combined Hormonal Contraceptive
By Age Group
15–24 Years
25–34 Years
35–44 Years
Above 44 Years
By End User
Hospitals
Homecare
Gynecology Centers
Clinics
Ambulatory Surgical Centers
By Country
GCC
Israel
Rest of Middle East
Africa
By Product
Oral Contraceptive Pills
Injectable Birth Control
Emergency Contraceptive Pills
Vaginal Ring
Transdermal Patches
By Hormone
Progestin Only Contraceptive
Combined Hormonal Contraceptive
By Age Group
15–24 Years
25–34 Years
35–44 Years
Above 44 Years
By End User
Hospitals
Homecare
Gynecology Centers
Clinics
Ambulatory Surgical Centers
By Region/Country
South Africa
Central Africa
North Africa
Company Profiles
The Female Health Company
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Teva Pharmaceutical Industries Limited
Bayer AG
Pfizer, Inc.
Mylan N.V.
Johnson & Johnson
Ansell Ltd.
Mayer Laboratories
Merck & Co., Inc.
Church & Dwight, Co., Inc.
Afaxys, Inc.
Allergan plc.
Agile Therapeutics
Apothecus Pharmaceutical Corporation.
Novartis AG
Sun Pharmaceutical Industries Ltd.
Cipla Limited
“*” marked represents similar segmentation in other categories in the respective section.